The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells by G. Streubel et al.
Short ArticleTheH3K36me2MethyltransferaseNsd1Demarcates
PRC2-MediatedH3K27me2 andH3K27me3Domains
in Embryonic Stem CellsGraphical AbstractH3K27me2 domain
H3K27me3 domain
K27me3
peak 
expansionH3K27me3
H3K36me2
H3K27me2
PRC2
Nsd1
H3K36me2
H3K27me3
Genome-wide
K27me3 
accumulation
H3K27me3
PRC2
Loss of Nsd1
de novo
K27me3 H3K27me3
H3K36me2
H3K27me2
Loss of Nsd1
Loss of Nsd1Highlightsd Endogenous interactome analysis identifies Nsd1 as a PRC2-
associated protein in ESCs
d PRC2-mediated H3K27me2 and Nsd1-mediated H3K36me2
co-localize genome-wide in ESCs
d Nsd1 loss leads to a reduction of H3K36me2 and a gain of
H3K27me3 across the ESC genome
d Nsd1 is required in ESCs to demarcate H3K27me3 and
H3K27me2 chromatin domainsStreubel et al., 2018, Molecular Cell 70, 371–379
April 19, 2018 ª 2018 Elsevier Inc.
https://doi.org/10.1016/j.molcel.2018.02.027Authors
Gundula Streubel, Ariane Watson,
Sri Ganesh Jammula, ...,
Nevan J. Krogan, Adrian P. Bracken,
Gerard Cagney
Correspondence
adrian.bracken@tcd.ie (A.P.B.),
gerard.cagney@ucd.ie (G.C.)
In Brief
The Polycomb repressor complex 2
(PRC2) deposits H3K27me2 and
H3K27me3 repressive histone
modifications in spatially defined
chromatin domains to maintain cellular
identity. Streubel et al. identify the
H3K36me2 methyltransferase Nsd1 as a
key modulator of PRC2 to restrict
H3K27me3 deposition and, thereby, to
demarcate H3K27me3 from H3K27me2
domains in ESCs.
Molecular Cell
Short ArticleThe H3K36me2 Methyltransferase Nsd1
Demarcates PRC2-Mediated H3K27me2
and H3K27me3 Domains in Embryonic Stem Cells
Gundula Streubel,1,2,8 Ariane Watson,2,8 Sri Ganesh Jammula,3 Andrea Scelfo,3 Darren J. Fitzpatrick,1 Giorgio Oliviero,2
Rachel McCole,1 Eric Conway,1 Eleanor Glancy,1 Gian Luca Negri,2 Eugene Dillon,2 Kieran Wynne,2 Diego Pasini,3,4
Nevan J. Krogan,5,6,7 Adrian P. Bracken,1,9,10,* and Gerard Cagney2,9,*
1Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, Ireland
2School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Dublin 4, Ireland
3Department of Experimental Oncology, European Institute of Oncology, Via Adamello 16, 20139 Milan, Italy
4Department of Health Sciences, University of Milan, Via A. di Rudinı`, 8, 20142 Milan, Italy
5Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA
6Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94148, USA
7Gladstone Institutes, San Francisco, CA 94158, USA
8These authors contributed equally
9These authors contributed equally
10Lead Contact
*Correspondence: adrian.bracken@tcd.ie (A.P.B.), gerard.cagney@ucd.ie (G.C.)
https://doi.org/10.1016/j.molcel.2018.02.027SUMMARY
The Polycomb repressor complex 2 (PRC2) is
composed of the core subunits Ezh1/2, Suz12, and
Eed, and it mediates all di- and tri-methylation of
histoneH3at lysine27 inhigher eukaryotes.However,
little is knownabout how the catalytic activity ofPRC2
is regulated to demarcate H3K27me2 andH3K27me3
domains across the genome. To address this, we
mapped the endogenous interactomes of Ezh2 and
Suz12 in embryonic stem cells (ESCs), and we
combined this with a functional screen for H3K27
methylation marks. We found that Nsd1-mediated
H3K36me2 co-locates with H3K27me2, and its loss
leads to genome-wide expansion of H3K27me3.
These increases in H3K27me3 occurred at PRC2/
PRC1 target genes and as de novo accumulation
within what were previously broad H3K27me2
domains. Our data support a model in which Nsd1
is a keymodulator ofPRC2 function required for regu-
lating the demarcation of genome-wide H3K27me2
and H3K27me3 domains in ESCs.
INTRODUCTION
Polycomb group proteins are a family of evolutionarily conserved
chromatin repressors with essential roles in maintaining cellular
identity in stem, progenitor, and differentiated cells (Holoch and
Margueron, 2017). Biochemically, Polycomb proteins form two
main multiprotein Polycomb repressive complexes, PRC1 and
PRC2 (Blackledge et al., 2015). The PRC2 complex consists of
three core components, Eed, Suz12, and one of the two histoneMH3K27methyltransferases Ezh1 or Ezh2, and it is responsible for
all H3K27me2 and H3K27me3 (Ferrari et al., 2014; Margueron
andReinberg, 2011). PRC2associateswith several sub-stoichio-
metric components, including Polycomb-like proteins PCL1-3,
JARID2, AEBP2, and EPOP, which are thought to confer distinct
functional effects, including modifying the activity and associa-
tion of the complex with chromatin (Holoch and Margueron,
2017). However, while methylations of H3K27 are understood
to play key roles in cellular identity, little is known about how
PRC2 is regulated to demarcate genome-wide domains of
H3K27me2 and H3K27me3 (Conway et al., 2015).
The H3K27me2 and H3K27me3 modifications are located in
different regions in the genome (Ferrari et al., 2014). The initial
genome-wide mapping studies of PRC2 components estab-
lished that they co-locate with H3K27me3 on the repressed pro-
moters of 10%–15% of all genes with key roles in development
and cell fate determination (Ringrose, 2007). The presence
of the H3K27me3 mark leads to the recruitment of the canonical
PRC1 (cPRC1). The genome-wide profiles of H3K27me3, PRC1,
and PRC2 change dynamically during cellular differentiation, and
they are required to maintain the repression of genes encoding
drivers of alternative lineages (Bracken and Helin, 2009). How-
ever, most deregulated genes in PRC2-depleted cells are not
direct H3K27me3 targets, suggesting that the H3K27me2 post-
translationalmodification (PTM)might have an underappreciated
role (Bracken et al., 2006; Ferrari et al., 2014). While all three
H3K27methylated states have been observed in H3K9me3-pos-
itive pericentric heterochromatin during early development (Pu-
schendorf et al., 2008), in the euchromatin of embryonic stem
cells (ESCs), H3K27me2 localizes at almost all regions except
the H3K27me1-positive gene bodies of actively transcribed
genes, the H3K27ac-positive regions at active enhancers, and
the H3K27me3-positive regions at Polycomb repressed gene
promoters (Ferrari et al., 2014; Lee et al., 2015; Wang et al.,
2018). The ubiquitous genome-wide profile of H3K27me2olecular Cell 70, 371–379, April 19, 2018 ª 2018 Elsevier Inc. 371
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Figure 1. Ezh2- and Suz12-Associated Proteins Dependent on an Intact PRC2 Complex in Embryonic Stem Cells
(A) Experimental outline of the endogenous affinity immunoprecipitations of Ezh2 and Suz12 from mouse ESC nuclear lysates followed by label-free quantitative
mass spectrometry. Immunoprecipitations were performed using monoclonal antibodies for Ezh2 (AC22), Suz12 (D39F), and IgG as a negative control. The
samples were subjected to liquid chromatography-tandem mass spectrometry (LC-MS/MS) in triplicates, and data were analyzed by MaxQuant software.
(B) Scatterplot representation of the enrichment of proteins in Ezh2 and Suz12 purifications as log2 ratios of the label-free quantification (LFQ) intensities over IgG
control from three independent replicates.
(C) Venn diagram showing the overlap between proteins enriched in Ezh2 and Suz12 immunoprecipitations (IPs) (log2 LFQ bait/IgG > 0.4).
(D) Experimental outline for label-free quantitative mass spectrometry of endogenous Ezh2 immunoprecipitations in wild-type compared to matched Eed/ and
Suz12 genetrap (GT) cells.
(E) Western blot analysis of Ezh2 immunoprecipitations in wild-type, Eed/, and Suz12GT ESCs with the antibodies as indicated. Oct4 is a negative control.
(F) High-confidence PRC2-associated proteins. Venn diagram analysis compares proteins identified in endogenous Ezh2 and Suz12 immunoprecipitations in
embryonic day (E)14 ESCs from (B) and those identified in Ezh2 immunoprecipitations in wild-type compared to Eed/ and Suz12GT ESCs.
(G) Western blot analysis of immunoprecipitations of IgG, Ezh2, and Suz12 performed on nuclear lysates of wild-type mouse ESCs.
See also Figure S1 and Table S1.suggests that its role is to act as a repressive blanket to prevent
the misfiring of cell-type-specific enhancers required for alterna-
tive lineages (Conway et al., 2015). Consistent with this idea, the
loss of PRC2 function inDrosophila cells leads to increases in the
transcription of intragenic mRNAs at sites previously located
within H3K27me2 domains (Lee et al., 2015).
Here we sought to identify factors that control the ability of
PRC2 to mediate H3K27me2 and H3K27me3 in ESCs. Our
observations describe a functional interplay between Nsd1 and
PRC2 that provides important new insights into how the demar-
cation of H3K27me2 and H3K27me3 domains are regulated.
RESULTS
Identification of Ezh2- and Suz12-Associated Proteins
that Depend on an Intact PRC2 Complex in ESCs
To generate a high-quality interaction network for the PRC2
complex in pluripotent cells, we performed mass spectrometry372 Molecular Cell 70, 371–379, April 19, 2018of endogenous immunoprecipitations of independent PRC2
subunits in matched wild-type, Eed/, and Suz12Gt mouse
ESCs (Figures 1A and 1D). Initially, we performed mass spec-
trometry of endogenous immunoprecipitations of Ezh2 and
Suz12 in wild-type ESCs (Figure 1B). The precipitated peptides
were analyzed for three independent replicates of both the
Ezh2 and Suz12 immunoprecipitations, then plotted against
each other in order to highlight the proteins that co-purify with
both PRC2 subunits (Figure 1B). This revealed that all core
PRC2 proteins (Ezh2, Suz12, and Eed), as well as all previously
characterized sub-stoichiometric subunits expressed in ESCs
(Mtf2/Pcl2, Phf19/Pcl3, Aebp2, Jarid2, Rbbp4/7, and Epop),
were immunoprecipitated by both antibodies (Figures 1B and
S1A; Table S1). In addition, 148 candidate PRC2 interaction
partners were also enriched in both the Ezh2 and Suz12 immu-
noprecipitations (Figure 1C; Table S1).
To determine which of the candidate proteins are dependent
on an intact PRC2 complex for their association with Ezh2 and
Suz12, we performed endogenous Ezh2 immunoprecipitations
coupled with mass spectrometry, this time on nuclear lysates
of Eed/ (Faust et al., 1998) and Suz12GT (Pasini et al., 2004)
in parallel with matched wild-type ESCs (Figure 1D). As ex-
pected, the lack of Eed led to decreased Suz12 in the Ezh2 im-
munoprecipitations (Figure 1E; Table S1), while the almost com-
plete lack of Suz12 in the Suz12GT cells led to decreased
amounts of Eed in the Ezh2 immunoprecipitations (Figure 1E; Ta-
ble S1). The Suz12GT ESCs have a low level of Suz12 due to low-
frequency skipping of the genetrap cassette, as described previ-
ously (Pasini et al., 2007). By combining these datasets, we iden-
tified a high-confidence set of 64 PRC2-interacting proteins (Fig-
ures 1F and S1B; Table S1). Among them were several proteins
previously described to be both physically and functionally
linked with PRC2, including Elongin B (Tceb2), Elongin C
(Tceb1), Ehmt1, and Ogt (Beringer et al., 2016; Chu et al.,
2014; Liefke et al., 2016; Mozzetta et al., 2014).
To evaluate our approach, we selected five candidate PRC2-
interacting proteins, including Elongin B (Tceb1), Nsd1, Dnmt3a,
Hells, and Ogt, and we performed independent co-immunopre-
cipitations of Ezh2 and Suz12 and confirmed their interaction
(Figure 1G). Of note, while the Ewsr1 protein did immunoprecip-
itate with Ezh2 using the AC22 antibody (Bracken et al., 2006),
it did not immunoprecipitate with a Suz12 antibody, demon-
strating the advantage of using antibodies for two different
PRC2 subunits (Figures 1B and 1G).
A Functional Screen for Modulators of PRC2-Mediated
H3K27me2 and H3K27me3
Next, we explored if depletion of any of thePRC2-interacting pro-
teins couldmodulate the levels or genomicbalanceofH3K27me2
and H3K27me3. To do this, we designed a high-content endon-
ribonuclease-prepared small interfering RNA (esiRNA) screen
of the 38 top-ranked PRC2-interacting proteins (Table S2),
including the core subunits Suz12, Ezh2, and Eed as positive
controls, and we used immunofluorescence for H3K27me2 and
H3K27me3 as functional readouts (Figure 2A). We used the
NTERA-2 pluripotent human embryonic carcinoma cell line
becauseof its amenability to esiRNA transfection and immunoflu-
orescence stainings. Efficient knockdowns were achieved for
32 of 38 targets (Figure S2A; Table S2), and immunofluorescence
for total histone H3 was performed to normalize the H3K27me2
and H3K27me3 stainings (Figure 2A; Table S3). As expected,
knockdown of EZH2, EED, and SUZ12 led to reduced levels of
both H3K27me2 and H3K27me3 (Figures 2B–2D; Table S3).
The knockdown of CHD4, OGT, and TOP2A (Figures 2B–2D)
led to reductions in the global levels of both H3K27 methylated
states (Figures 2B–2D; Table S3), consistent with previous re-
ports of functional interplay with PRC2 (Gambetta et al., 2009;
Sparmann et al., 2013; Thakurela et al., 2013). Western blot anal-
ysis of H3K27me2 and H3K27me3 levels in cells depleted of
TOP2A and OGT validated these observations (Figure S2B).
Interestingly, knockdown of the H3K36me2 histone meth-
yltransferase NSD1 had the strongest positive effect on
H3K27me3 levels (Figures 2B, 2D, and S2B). Importantly, inde-
pendentwesternblot analysis of cells depletedofNSD1validated
these observations (Figure S2B), while endogenous Ezh2 immu-
noprecipitations on nuclear lysates of Eed/ in parallel withmatched wild-type ESCs suggested that Nsd1 requires an intact
PRC2 complex for its interaction with Ezh2 (Figure S2C). Finally,
an immunoprecipitation of Nsd1 inmouse ESCs confirmed that it
pulls down both Ezh2 and Suz12 proteins (Figure S2D). Impor-
tantly, while more than 40 peptides specific for mouse Nsd1
were identified in the Ezh2 and Suz12 mass spectrometry exper-
iments (Figure S2E), the related Nsd2 or Nsd3 proteins were not
detected (Table S1), consistent with their lower mRNA expres-
sion levels compared toNsd1 inmouse ESCs (Figure S2F).More-
over, we did not detect any other H3K36me2methyltransferases
in the Ezh2 and Suz12 immunoprecipitations in ESCs (Table S1).
Loss of Nsd1-Mediated H3K36me2 Leads to De Novo
Accumulation of H3K27me3 Genome-wide
To characterize the requirement of Nsd1 for H3K27me3 inmouse
ESCs, we depleted it using two independent small hairpin RNAs
(shRNAs), andwe observed global increases inH3K27me3 levels
in both serum/leukemia inhibitory factor (LIF) (Figures 3A and
S3A) and 2i/serum/LIF (Figures S3A and S3B) containing growth
medium. As expected, the levels of H3K36me2 were reduced,
while the bulk levels of H3K27me2 did not appear to change (Fig-
ures 3A and S3B). Of note, while the knockdown of the Setd2
methyltransferase led to a global loss of H3K36me3, it did not
affect H3K27me3 levels (Figure S3B). Moreover, the changes in
bulk H3K27me3 levels were not a consequence of phenotype
changes in the ESCs, since the proliferation rate and expression
of pluripotency markers were unaffected in the Nsd1-depleted
ESCs (Figures S3C–S3E). Taken together, these results suggest
that reductions in the global levels of H3K36me2, but not
H3K36me3, can specifically lead to global increases in the levels
of PRC2-mediated H3K27me3.
We next performed quantitative chromatin immunoprecipita-
tion relative to a reference exogenous genome (ChIP-Rx) of
H3K27me3 and H3K36me2, andwe plotted the changes at inter-
vals (or bins) of 50 kb between control and Nsd1-depleted ESCs
(Figure 3B). This confirmed that the majority of genomic regions
that lose H3K36me2 concomitantly gain H3K27me3 (Figure 3B;
99.1% for shNsd1.1 and 97.0% for shNsd1.2). As a control for
the H3K27me3 antibody, we confirmed that it is capable of
recognizing its epitope even in the presence of H3K36me2
on the same histone H3 tail (Figure S3F). Average plots of
H3K36me2 and H3K27me3 across 40-kb genomic intervals
up- and downstream of the center of all H3K27me3-positive re-
gions, in both control and Nsd1-depleted ESCs, confirmed that
the relative loss of H3K36me2 at these sites directly correlated
with the degree of accumulation of H3K27me3 (Figure 3C).
Furthermore, a heatmap representing all regions with a gain
in H3K27me3 signal (n = 3,523) in the shNsd1.1 sample and
the corresponding H3K36me2 signal intensity confirmed the
relationship between both histone marks (Figure S3G). More-
over, we also found that weaker H3K27me3 peaks were more
susceptible to an increase in H3K27me3 (Figure S3H).
We next quantified the changes of H3K27me3 and H3K36me2
at gene promoters, gene bodies, and intergenic regions, and
we represented the distributions as boxplots (Figure 3D). This
revealed that the gains of H3K27me3 and corresponding
decreases in H3K36me2 occurred throughout the genome and
were not restricted to any particular regions. Therefore, whileMolecular Cell 70, 371–379, April 19, 2018 373
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Figure 2. A Functional Screen for Modulators of PRC2-Mediated H3K27me2 and H3K27me3
(A) Experimental outline of functional screen of PRC2-associated proteins using H3K27me2 and H3K27me3 as functional readouts. The pluripotent embryonic
carcinoma cell line NTERA-2 was reverse-lipofected with esiRNAs in a 96-well-plate format. Cells were stained for H3K27me2, H3K27me3, total histone H3, and
Hoechst 72 hr post-transfection, and immunofluorescence signals were captured with CellInsight. The signals were normalized using histone H3 and Hoechst
and then standardized using Z score. To adjust for multiple comparison, the p values were Bonferroni corrected.
(B) Graphs showing changes in H3K27me3 levels following esiRNA-mediated knockdowns, as indicated. The Z scores for each knockdown condition from four
replicates are represented.
(C) Graphs showing changes in H3K27me2 levels following esiRNA-mediated knockdowns, as indicated. The Z scores for each knockdown condition from four
replicates are represented.
(D) Representative immunofluorescence stainings of H3K27me2, H3K27me3, and histone H3 in cells transfectedwith control or esiRNAs targeting EZH2, SUZ12,
and selected PRC2-associated proteins. The red boxes highlight global decreases in H3K27me2/3 levels, while the green box highlights a global increase in
H3K27me3 levels in NSD1-depleted cells.
See also Figure S2 and Tables S2 and S3.H3K27me3 is relatively high at promoter regions, it further in-
creases in these regions upon depletion of Nsd1. In addition,
while H3K27me3 is lower or absent on most gene bodies
and intergenic regions, it accumulates in these regions in
Nsd1-depleted cells. Consistent with this, we observed that
H3K36me2 is detected throughout the genome and becomes
depleted at promoters, gene bodies, and intergenic regions in
Nsd1-depleted cells, independently of location.
Taken together, these observations led us to speculate that
Nsd1-mediated H3K36me2 functions as a modulator of PRC2
activity to restrict the accumulation of H3K27me3 throughout
the genome in ESCs.
Nsd1 Collaborates with the PRC2 Complex to
Demarcate Regions of H3K27me2 and H3K27me3
To explore the degree of correlation or anti-correlation of the
di- and tri-methylated forms of H3K27 andH3K36, we performed374 Molecular Cell 70, 371–379, April 19, 2018a principal component analysis (Figure 4A). This revealed a
strong anti-correlation between H3K36me3 and H3K27me3, as
reported previously (Ernst and Kellis, 2010). To our surprise,
we observed a strong positive correlation between H3K27me2
and H3K36me2, despite previous demonstrations that both
H3K36me2 and H3K36me3 peptides block PRC2-mediated
H3K27me2/3 (Schmitges et al., 2011; Yuan et al., 2011).
Supporting this observation, a positive correlation between
H3K27me2 and H3K36me2 (Figure 4B, left panel), a moderate
correlation between H3K27me3 and H3K36me2 (Figure 4B, mid-
dle panel), and a strong negative correlation betweenH3K27me3
and H3K36me3 (Figure 4B, right panel) were also observed in
correlation plots.
The strong positive correlation between H3K27me2 and
H3K36me2 prompted us to more closely monitor the
H3K27me3 in the context of H3K27me3 and H3K27me2 do-
mains (Figures 4C and S4A). This revealed that the increases in
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Figure 3. Loss of Nsd1-Mediated H3K36me2 Leads to Genome-wide Accumulation of H3K27me3
(A) Western blot analysis of chromatin lysates of ESCs transduced with control or two independent shRNAs targeting Nsd1 (shNsd1.1 and shNsd1.2).
(B) Scatterplot showing the relationship between the genome-wide changes in H3K27me3 and H3K36me2. The genome was segmented into small bins at a
resolution of 50,000 bp, and the difference in the number of ChIP-Rx-normalized reads of H3K36me2 or H3K27me3 between control and Nsd1-depleted cells
was plotted. The percentage of bins found in each quadrant is shown.
(C) Average ChIP-Rx signal profiles of H3K27me3 and H3K36me2 showing a depletion of H3K36me2 in regions enriched (false discovery rate [FDR] = 0.1) for
H3K27me3 in wild-type and Nsd1-depleted cells. The enriched regions were extended ±40 kb from their midpoint.
(D) Distribution of H3K27me3 and H3K36me2 ChIP-Rx-normalized reads within gene promoters (±2.5 kb of transcription start site [TSS]), gene bodies, and
intergenic regions in wild-type and Nsd1-depleted embryonic stem cells.
See also Figure S3.H3K27me3 levels upon Nsd1 depletion occurred within
H3K27me3 domains, but also de novo within H3K27me2 do-
mains (Figures 4C and S4A). This de novo H3K27me3 accumu-
lation within intergenic H3K27me2 domains correlated with
reduced H3K27me2 (Figures 4D, 4E, and S4C), but without
gene expression changes (Figure S4B). Interestingly, these
changes correlated with increased Suz12 binding in both do-
mains, consistent with PRC2’s ability to bind its own mark (Fig-
ures S4D and S4E).
Altogether, our data demonstrate that, in ESCs, Nsd1 is an
important regulator of H3K27me3 placement by PRC2, prevent-
ing an aberrant accumulation of the mark. We propose a mecha-
nism by which Nsd-mediated H3K36me2 functions to restrict
the deposition of H3K27me3 and, in doing so, contributes to
the demarcation of PRC2-mediated H3K27me2 and H3K27me3
domains.DISCUSSION
An outstanding question in Polycomb biology is how PRC2 is
regulated to deposit H3K27me2 and H3K27me3 marks across
the genomes of higher eukaryotic cells. Our data are consistent
with a role for Nsd1-mediated H3K36me2 in modulating PRC2
activity across the genome, such that high H3K36me2 correlates
with PRC2-mediated H3K27me2 deposition while low levels of
H3K36me2 correlate with increased H3K27me3. More broadly,
we propose that H3K36me2 modulates PRC2 activity by
preventing random placement of H3K27me3 throughout the
genome.
The co-location of H3K27me2 and H3K36me2 PTMs
throughout the majority of the ESC genome suggests that
PRC2 cooperates with Nsd1 at these locations. Moreover, while
H3K36me2 is lower at H3K27me3-enriched regions, it is stillMolecular Cell 70, 371–379, April 19, 2018 375
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Figure 4. Nsd1-Mediated H3K36me2 Modulates PRC2 Activity to Demarcate Regions of H3K27me2 and H3K27me3
(A) Biplot representing the degree of correlation between the indicated H3K27 andH3K36methylation states. Correlation coefficients with the first component are
K36me2 = 0.8873187, K36me3 = 0.3305159, K27me2 = 0.8602497, and K27me3 = 0.5469931.
(B) Plots showing the genome-wide correlation between the H3K27me2 and H3K36me2 (left), H3K27me3 and H3K36me2 (middle), and H3K27me3 and
H3K36me3 (right) modifications. The complete genome was fragmented into small bins of 10-kb resolution, and the total number of reads for each modification
within each bin was computed and normalized to sequencing depth. Each modification type was then scaled to 0–1 and the R coefficient was determined with
Pearson correlation. The p values for all three plots are <2.2e16 (based on Pearson’s product moment correlation coefficient, followed by t-distribution).
(C) Genome viewer representations of ChIP-Rx-normalized reads for H3K27 and H3K36 methylations at two loci, showing the increases of H3K27me3 in both
pre-existing H3K27me2 (green) and H3K27me3 (red) domains in Nsd1-depleted ESCs. H3K27me2 was normalized to reads per genome content (RPGC).
(D) ChIP-qPCR analysis of H3K27me3, H3K36me2, and H3K27me2 changes at two H3K27me3 domains (red) and two H3K27me2 domains (green) using the
primers indicated in (C). The means ± SD of technical replicates of a representative experiment are shown.
(E) Boxplot summary of ChIP-qPCR analyses of H3K27me3, H3K36me2, and H3K27me2 in shNT and shNsd1 cells at 12 independent genomic sites (primer pairs)
representing H3K27me3 domains and 12 independent genomic sites representing H3K27me2 domains. The median (thick line) and the most outliers (thin lines)
are indicated.
See also Figure S4.present, as are low levels of H3K27me2. This co-localization
of H3K27me2 and H3K36me2 is difficult to reconcile with
the in vitro demonstration that synthetic H3K36me2- or
H3K36me3-modified peptides inhibit PRC2-mediated di- and
tri-methylation of H3K27 (Schmitges et al., 2011; Yuan et al.,
2011). However, recent work clarified that, while symmetrically
modified nucleosomes by H3K36me3 or H3K4me3 do indeed
block PRC2 methyltransferase activity, asymmetrically modified
nucleosomes do not (Voigt et al., 2012). Therefore, it is possible
that the co-location of H3K36me2 and H3K27me2/3 observed
by ChIP-Rx in this study might be due to asymmetric deposition376 Molecular Cell 70, 371–379, April 19, 2018of the PTMs. Nonetheless, in line with our findings, mass spec-
trometric quantifications of histone PTMs demonstrated that
H3K36me2 and H3K27me2 PTMs co-occur on the same histone
H3 tails (Jung et al., 2013; Yu et al., 2016). However, on the level
of chromatin, we and others have not been able to chromatin-
immunoprecipitate PRC2 or NSD1 at H3K27me2/H3K36me2-
positive locations (data not shown; Ferrari et al., 2014), suggest-
ing the interactions are transient and not stable. A potential
explanation for this is that the ChIP method does not capture
proteins that interact with chromatin with a short residence
time (Schmiedeberg et al., 2009). Interestingly, the levels of
H3K36me2 accumulate within 2 hr after DNA replication, similar
to PRC2-mediated H3K27me2 (Alabert et al., 2015). Therefore,
it is possible that PRC2 and NSD1 cooperate to mediate their
respective H3K27me2 and H3K36me2 marks by a mechanism
that is coupled with DNA replication.
It is likely that other H3K36me2 methyltransferases function to
demarcate H3K27me2 and H3K27me3 in other cells types. Sup-
porting this, Lu and colleagues showed that knockdown of NSD2
and NSD3 in mesenchymal cells leads to global increases in
H3K27me3 (Lu et al., 2016). In Drosophila, the Ash1 Trithorax
protein, which mediates H3K36me2, counteracts PRC2-medi-
ated H3K27me3 deposition on Polytene chromosomes (Dorighi
and Tamkun, 2013). Furthermore, the mammalian Ash1 ortholog
Ash1L counteracts Polycomb-mediated repression by promot-
ing H3K36me2 at gene bodies of Hox genes (Miyazaki et al.,
2013). Although our data suggest that Nsd1-mediated
H3K36me2 has a general regulatory impact on H3K27me3
genome-wide, it is also possible that the Nsd1 protein itself or
an H3K36me2-binding protein, rather than the modification,
may inhibit PRC2 activity, e.g., by sterical competition. Finally,
in terms of a potential role in directing PRC2 activity to CpG
islands, it is interesting to note that H3K36me2 levels are lower
at promoters with CpG islands compared to non-CpG island
promoters in ESCs (Blackledge et al., 2010).
Our results have implications for our understanding of the po-
tential mechanisms by which the NSD1–3 proteins contribute to
development and disease. Consistent with an important role for
Nsd1 during mouse development, its loss leads to early lethality
and the inability to activate Hox genes (Rayasam et al., 2003). As
depletion of Polycomb group proteins causes embryonic devel-
opmental defects and a deregulated Hox gene (Bracken and
Helin, 2009), one could speculate that theNsd1 knockout pheno-
type is related to aberrantly high levels of PRC2-mediated
H3K27me3. Our results suggest that the frequent deregulation
of the NSD1–3 proteins in cancer and the oncogenic H3K36M
mutation (Brien et al., 2016; Lu et al., 2016) are associated with
deregulated demarcation of PRC2-mediated H3K27me2 and
H3K27me3 domains. It will be important to determine the conse-
quences on altered H3K27me2 and H3K27me3 profiles in these
cancers. In the broader context, one could speculate that the
loss of function of Nsd proteins and H3K36M mutations would
phenocopy EZH2 change-of-function mutations and, as such,
could be targeted by PRC2 inhibition strategies (Conway et al.,
2015). Another potential implication of the functional interplay
between NSD1 and EZH2 described here might provide new
insight into the pathogenic defects in Sotus and Weaver over-
growth syndromes. Constitutional NSD1 loss-of-function and
EZH2 change-of-function mutations cause Sotos and Weaver
syndromes, respectively, yet both share considerable pheno-
typic overlap (Tatton-Brown and Rahman, 2013). Our data sug-
gest that the NSD1 and EZH2 mutations in these syndromes
would lead to increased levels and redistribution of H3K27me3
coupled with decreased levels of H3K27me2. These potentially
shared epigenomic defects could be explored in order to under-
stand the common phenotypic features of these syndromes.
We propose that H3K36me2 functions to restrict the accu-
mulation of PRC2-mediated H3K27me3 across the genome
in ESCs. Our study adds to the growing evidence of interplaybetween methylations at the H3K27 and H3K36 residues, and
it provides new insights into the regulation of PRC2 activities in
higher eukaryotic cells.
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Human: NTERA-2 cl.D1 ATCC RRID: CVCL_3407; ATCC CRL-1973
Mouse: ES cell line E14 Pasini laboratory N/A Strain of origin 129P2/Ola
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pLKO.TRC1.shmNsd1.1, puro Sigma-Aldrich TRCN0000123381
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Bracken (adrian.bracken@tcd.ie).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mammalian cell culture
Eed KO ESCs and parental cell lines were provided by Dr. A Wutz (Schoeftner et al., 2006), while E14 ES and the Suz12GT cell line
were provided by Dr. D. Pasini (Pasini et al., 2004), (originated from 129P2/Ola, male). Mouse embryonic stem cells were grown on
gelatinized culture dishes in GMEMmedia (Sigma-Aldrich) supplemented with 15%FBS (GIBCO) (v/v), 1000 U/ml leukemia inhibitory
factor (EMD Millipore), 100 U/ml penicillin, 100 U/ml streptomycin (GIBCO), 2 mM GlutaMAX (GIBCO), 1:100 MEM non-essential
amino acids (GIBCO), 1 mM sodium pyruvate (GIBCO) and 50 mM b-mercaptoethanol (Sigma-Aldrich). For growth in 2i growth con-
ditions, the GSK3 inhibitor CHIRON99021 (Millipore) andMEK inhibitor PD0325901 (Millipore) were added at a final concentrations ofMolecular Cell 70, 371–379.e1–e5, April 19, 2018 e2
3 mM and 1 mM, respectively. For embryoid bodies were generated with the hanging drop method as previously described (Pasini
et al., 2007). The NTERA-2 cells (pluripotent embryonal carcinoma, male, ATCC CRL-1973) and HEK293T cells (human embryonic
kidney, contains the SV40 T-antigen, female, ATCC CRL-3216) were grown in DMEM (Sigma-Aldrich) supplemented with 10% (v/v)
FBS (GIBCO), 100 U/ml penicillin and 100 U/ml streptomycin (GIBCO). All cell lines were propagated at 37C with 5% CO2.
Stable cell lines
To obtain stable knockdowns in mouse ESCs, pLKO.1 lentiviral shRNA expressing vectors directed against mouse Nsd1
(pLKO.TRC1.shmNsd1.1; GCTCGTTAAGACACCAGGAAA; TRCN0000123381; Sigma-Aldrich) and pLKO.TRC1.shmNsd1.2;
CCACTGTTCTTCTTTCCTTAT; TRCN0000123379; Sigma-Aldrich; CCAGATTTCTTTCTCCGCCTT) and Setd2, (TRCN0000238533;
TRCN0000238536), (Ferrari et al., 2014) were used. A control shRNA, shLuciferase (Sigma, SHC007) was used. Lentiviral particles
were generated in HEK293T transfected with pLKO.1 and plasmids encoding the necessary packaging (pPax8) and envelope pro-
teins (pVSVG). Lentiviral particles were added to E14 ES cells together with 10 mg/ml Polybrene (Sigma-Aldrich) for 12-16 hours and
then selected with 2 mg/ml puromycin.
METHOD DETAILS
Antibodies
For western blotting, the antibodies used were Ezh2-BD43 (Pasini et al., 2004), Eed-AA19 (Bracken et al., 2003), Suz12 (Cell
Signaling, D39F6), Oct4 (Abcam, Ab19857), ElonginB (also known as Tceb2) (Santa Cruz, sc-11447), Nsd1 (Abbexa, abx135901),
Dnmt3a (Abcam, ab13888), Hells (Bethyl, A300-226A), Ogt (Santa Cruz, sc-32921), Ewsr1 (Santa Cruz, sc-6533), H3K27me3 (Cell
Signaling, C36B11), H3K27me2 (Cell signaling, D18C8), H3K27me1 (Active Motif, MABI 0321), Histone H3 (Abcam, ab1791),
H3K36me2 (Cell Signaling, C75H12), H3K36me3 (Cell Signaling, D5A7), Top2a (Santa Cruz, sc-13058), Ogt (Santa Cruz,
sc-32921), bTubulin (Santa Cruz, sc-9104). HRP-linked secondary antibodies, anti-rabbit (Sigma, A0545), anti-light chain rabbit
(Abcam, ab99697), anti-mouse (Merck, 401253) and anti-goat (Santa Cruz, sc-2020) were used. For immunoprecipitations, the
antibodies used were Ezh2-AC22), (Bracken et al., 2006), Suz12 (Cell Signaling, D39F6), rabbit IgG (EMD Millipore, 12-370) and
mouse IgG (EMD Millipore, 12-371). For Chromatin-Immunoprecipitations, the antibodies used were H3K27me3 (Cell signaling,
C36B11), H3K27me2 (Cell signaling, D18C8), H3K36me2 (Abcam, ab9049, ab176921), Histone H3 (Abcam, ab1791). For Immuno-
fluorescence experiments, the antibodies H3K27me3 (Cell Signaling, C36B11), H3K27me2 (Cell Signaling, D18C8), H3K27me1
(Active Motif, MABI 0321) and Histone H3 (Active Motif, MABI 0301) and Alexa Fluor-conjugated secondary antibodies (A-11012,
A-21242, A-21131) were used.
Production of esiRNAs and transfections
Endonribonuclease-prepared siRNAs (esiRNAs) were synthesized in-house as described in Heninger and Buchholz (2007). Briefly,
target regions for each gene of interest were designed using DEQOR software (Henschel et al., 2004). Following in vitro transcription
and purification of these target regions, double-stranded RNAs (dsRNAs) were digested into 21 nt fragments using E. coli purified
RNase III mutant E38A. The resulting esiRNAs consisted of a heterozygous population of 21 nt siRNA molecules for each gene of
interest. NTERA-2 andmouse ESCs were transfected with esiRNAs using Lipofectamine RNAiMAX, according to the manufacturer’s
protocol. For transfections in ESCs, 300 ng of esiRNAs were used together with 3 mL RNAiMax in 600 mL Optimem (GIBCO) for
reverse transfection of 1.8x105 cells per 6-well in Penicillin and Streptomycin free ES growth medium. Following incubation for
16 hours, the medium was changed and the cells were harvested 72 h post transfection. The NTERA-2 cells were transfected
for 72 h in a 96-well format containing 6x103 cells and were reverse transfected with 25 ng esiRNA together with 0.15 mL RNAiMax.
Functional esiRNA screen for H3K27me2 and H3K27me3
The esiRNA-screen was performed in 96-well format in four biological replicates, with each biological replicate containing two tech-
nical replicates. The NTERA-2 cells were reverse transfected with Lipofectamine RNAiMAX and fixed 72 h following transfection for
immunofluorescence and Hoechst 33342 (Sigma-Aldrich) staining. Nuclei were stained with Hoechst 33342 and this signal was used
to mask the nuclei of cells. In order to exclude apoptotic and mitotic cells from the analysis, gating parameters were carefully set,
based on variations of intensity within each cell, and in the cell size and shape. Imaging was performed on a CellInsight Personal
Image Cytometer (Thermo Scientific), measuring cell count, histone H3 and global H3K27me1/2/3 intensities per cell. All H3K27
methylation intensities were normalized to the total histone H3 to rule out perturbations which affected histone abundance rather
than specifically altering methylation levels. All data was standardized using Z-scoring and subsequently p values were determined
to measure the significance of the deviation of each sample’s mean from the mean of the pool of controls. Bonferroni correction was
used to adjust for multiple comparisons.
Western blotting
For western blotting of total protein, whole cell lysates were generated by lysing cells in IPH buffer containing protease inhibitors
(50 mM Tris pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP40 and protease inhibitors 2 mg/ml aprotinin, 1 mg/ml leupeptin,
10 mg/ml PMSF, and 0.5 mM DTT). To obtain chromatin associated proteins, the lysates were incubated with Benzonasee3 Molecular Cell 70, 371–379.e1–e5, April 19, 2018
(125 U/mg protein) after addition of 7 mMMgCl2 (final 2 mM) at 4C. For Western Blotting of chromatin fractions, cells were harvested
and processed as for CHIP analysis and the sonicated chromatin lysates were used for western blots. The protein lysates were
separated on SDS–PAGE gels and transferred to nitrocellulose membranes. Membranes were subsequently probed using the
relevant primary and secondary antibodies, and relative protein levels were determined by chemiluminescence. For Figures 1
and 2 (and Supplemental Information), western blots were exposed to X-ray films. For Figures 3 and 4 (and Supplemental
Information), western blot chemoluminescence signals were captured with the ChemiDoc Imaging Systems (BioRad).
Peptide dot blots
Modified peptides representing Histone H3 N-terminal amino acids 20-40 (LATKAARKSAPATGGVKKPHR) were purchased
from Peptide 2.0 1 mg of peptides were spotted onto nitrocellulose membrane and allowed to dry. Membranes were blocked in
5% skimmed milk in PBS-T (0.1%) for 1 hour at room temperature followed by probing with the relevant primary and secondary
antibodies. Proteins were visualized by chemiluminescence.
Immunoprecipitations and proteomic analysis
Purification of endogenous multiprotein complexes was performed essentially as previously described (Oliviero et al., 2016). Briefly,
nuclear pellets were lysed in high salt containing buffer C (20 mM HEPES at pH 7.6, 20% [v/v] glycerol, 0.42 M NaCl, 1.5 mMMgCl2,
0.2 mM EDTA, aprotinin 1 mg mL1, leupeptin 10 mg mL1, PMSF 1mM) and subsequently dialyzed against buffer C-100 (20 mM
HEPES at pH 7.6, 20% [v/v] glycerol, 0.2mMEDTA, 100mMKCl, 1.5mMMgCl2, 0.2mMEDTA). 10 mg of antibodies were chemically
cross-linked with dimethyl pimelimidate (Sigma-Aldrich) to 40 mg of Sepharose A beads (Sigma-Aldrich) and immunoprecipitations
were performed in the presence of 250 Units Benzonase permg protein (Sigma-Aldrich, E1014-5KU). 2mg nuclear lysates were used
for each immunoprecipitation. After 3 hours incubation at 4C, immuno-complex bound beads were washed five times with C-100
buffer supplemented with 0.02% NP-40 and with one time in Phosphate buffered saline (PBS). Proteins were either eluted with
2xSDS sample buffer for western blot analyses or digested with Trypsin for mass spectrometry analyses.
Mass spectrometry
All in-solution tryptic digestions were performed as described previously (Wisniewski et al., 2009). The peptides were analyzed with a
Q Exactive mass spectrometer coupled with an EASY-nLC HPLC system (Thermo Fisher) and an in-house packed C18 column
(New Objective). Parent ion spectra (MS1) were measured at resolution 70,000, AGC target 3e6. Tandem mass spectra (MS2,
up to 10 scans per duty cycle) were obtained at resolution 17,500, AGC target 5e4, collision energy of 25. All mass spectrometry
data were processed using the MaxQuant software, version 1.3.0.5 (Cox and Mann, 2008) using the mouse UniProt database.
The following search parameters were used; Fixed Mod: carbamidomethylation, Variable Mods: methionine oxidation, Trypsin/P
digest enzyme, Precursor mass tolerances 6 ppm, Fragment ion mass tolerances 20 ppm, Peptide FDR 1%, Protein FDR 1%.
Volcano plots were generated using Perseus software, version 1.4 (Tyanova et al., 2016). Volcano plots were generated using the
parameters FDR 0.05, and S 0.5. To generate the overlap between the Ezh2 and Suz12 IPs (Figure 1B), all proteins detected with
a cut-off of at least 0.4 t test LFQ intensities in the Suz12 and Ezh2 IP over IgG were used. For wild-type compared to knockout
ES cells (Figure 1F), those proteins detected with > 0.05 t test difference in LFQ intensities in E36 and in E14 wild-type cells over
the respective knockout cell line were used to generate the Venn diagrams. All 40S and 60S ribosomal proteins were not considered
and removed from the list.
ChIPs, ChIP-Rx and library preparation
All ChIP experiments were performed as described previously (Bracken et al., 2006). We also performed quantitative chromatin
immunoprecipitation relative to a reference exogenous genome (ChIP-Rx) coupled with massively parallel DNA sequencing for
the genome-wide mapping of histone modifications, as described previously (Orlando et al., 2014). For this, a total of 5% of
Drosophila chromatin at a sheared size of 200-300 bp was added to each ChIP reaction. For ChIP-RX experiments, the precipitated
DNA was quantified using the Qubit dsDNA HS Assay Kit (Thermo Scientific, Q32854). A total of 1-5 ng of DNA from each ChIP-RX
experiment was used for library preparation using the Illumina ChIP-Seq Sample Prep Kit (IP-102-1001) and Multiplexing Sample
Preparation Oligonucleotide Kit (PE-400-1001). Following adaptor ligation, the DNA was PCR amplified for 15 cycles. DNA purifica-
tion steps were then performed using DNA SPRI bead (Beckman Coulter, B23318) cleanup. The quality of the DNA libraries was
assessed using a high sensitivity Bioanalyzer Chip (Agilent). The resultant libraries were then used for cluster generation and
sequencing using HiSeq 2000 (Illumina) and 50 bp read length.
Next generation sequencing analysis
Sequencing readswere aligned to themouse reference genome (mm9) using Bowtie (Langmead et al., 2009). Only unique alignments
were retained for downstream analyses. For ChIP-Rx experiments, sequencing reads were also aligned to the Drosophila genome
(dm6) and normalization factors calculated (Orlando et al., 2014). Ambiguous reads, i.e., reads that aligned to both mouse and
Drosophila genomeswere removed from all downstream analyses. Bigwig fileswere generated at a resolution of 10bp using the bam-
Coverage utility from the deepTools suite (Ramı´rez et al., 2016) and data were subsequently visualized as tracks using the UCSC
genome browser (Kent et al., 2002). Genome-wide differences in the wild-type and Nsd1 depleted cells for H3K27me3 andMolecular Cell 70, 371–379.e1–e5, April 19, 2018 e4
H3K36me2 were visualized by partitioning the genome into bins at a 50kb resolution and subtracting wild-type ChIP-Rx normalized
read counts in each bin from the corresponding counts in the knock-downs. Data were scaled for visualization purposes. ChIP en-
riched regions (peaks) were computed using macs2 (Zhang et al., 2008) for the H3K27me3 wild-type and Nsd1.1 and Nsd1.2
depleted cells at a FDR of 0.1. Average profiles were constructed for these regions (midpoint of peak ± 40kb) using ngsplot (Shen
et al., 2014) for H3K27me3 and their corresponding sites in H3K36me2. Genome-wide correlations between histone modifications
were computed by partitioning the mouse genome into 10kb bins and comparing the normalized reads counts within each bin.
Normalized read counts were scaled to a 0-1 range. Furthermore, we isolated those 10kb bins that had a gain in H3K27me3 greater
than 0.2 reads per reference per million (RPM) and a loss of less than 0.2 RPM in H3K36me2. Promoters (TSS ± 2.5kb), gene bodies
and intergenic regions overlapping these bins were obtained and the ChIP-Rx normalized read counts of these regions represented
as boxplots. Additionally, principal component analysis (PCA) using FactoMineR (Leˆ et al., 2008) was performed to understand the
degree of correlation between the different histone modifications.
Quantitative real-time PCR
Total RNAwas extracted from cells using the RNeasy kit (QIAGEN) according to manufacturer’s protocol. RNAwas used to generate
cDNA by reverse transcriptase PCR using the TaqMan Reverse Transcription kit (Applied Biosytems). Relative mRNA expression
levels were determined using the SYBR Green I detection chemistry (Applied Biosystems) on the ABI Prism 7500 Fast Real-Time
PCR System. The ribosomal constituent Rplpo or Gapdh were used as a control gene for normalization. For Box-Whisker-Plots,
the online tool BoxPlotR (http://shiny.chemgrid.org/boxplotr) was used. The Primer sequences are available in Table S4.
QUANTIFICATION AND STATISTICAL ANALYSIS
All qPCR data are presented as themean and standard deviation from either technical replicates or independent biological replicates
(n represents biological replicates). The information is indicated in the Figure legends, accordingly. In Figure 1, for peptide mapping,
the MaxQuant software, version 1.3.0.5 (Cox and Mann, 2008) was used with an FDR of 1% for peptides and proteins. Volcano plots
relating to Figures 1 and S1, Tables S1 and S2, were generated using Perseus software, version 1.4, as previously described, with
FDR 0.05, and S 0.5. In the esiRNA screen in Figure 2 and Table S3, immunofluorescence intensities were measured and determined
by the built-in software of the CellInsight Personal Image Cytometer (Thermo Scientific). All immunofluorescence intensities were
subsequently standardized using Z-scoring, by the following formula: z = x – m / s, where x is the well intensity, m is the mean control
intensity for the plate (n = 8 control wells per plate), and s is the standard deviation of the control wells in the plate. Prism software
(version 6.07, GraphPad) was used to perform one-way ANOVA analysis of the standardized intensities of all plates (4 independent
replicates, with 2 technical replicates each), comparing the mean of each sample to the mean of the negative controls. Bonferroni
correction was used to control for multiple comparisons and confidence intervals were computed for 95% confidence with statistical
significance defined using an alpha of 0.05 after correction. In Table S3, significance is denoted as follows: p < 0.05 = *, p < 0.01 = **,
p < 0.001 = ***, and p < 0.0001 = ****. Finally, for the ChIP-Rx statistical analysis in Figure 4B, the Pearson correlation coefficients and
p values were computed using the cor.test function in the R programming language. Further details can be found in the figure
legends.
DATA AND SOFTWARE AVAILABILITY
The accession number for the H3K27me3 ChIP-Rx, H3K36me2 ChIP-Rx, and ChIP-seq data reported in this paper is GEO:
GSE107773. The accession numbers for the publicly available H3K27me3 and H3K36m3 data reported in this paper are GEO:
GSM1234538 and GSM1234540, respectively. The accession numbers for the publicly available RNA-seq data from ESC differen-
tiation into embryoid bodies reported in this paper are GEO: GSE51006, GSM1249334, andGSM1249336. The accession number for
the proteomics data reported in this paper is PRIDE: PXD005381. Original images have been deposited to Mendeley Data and are
available at: https://data.mendeley.com/datasets/4pzh3gjkm9/draft?a=0297530d-c12d-45ee-bba1-867c3103c13e.e5 Molecular Cell 70, 371–379.e1–e5, April 19, 2018
